PEN logo

Penumbra (PEN) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

18 September 2015

Indexes:

Not included

Description:

Penumbra, Inc. is a medical company focused on innovative treatment methods, which designs, develops, manufactures, and sells medical devices. The company's products are aimed at two main segments: vascular diseases and neurosurgery. In both of these markets, the company offers key products: thrombectomy systems - for removing blood clots (thrombi) and embolization systems - for treating patients with various sizes of aneurysms and other vascular and nervous disorders. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.

Events Calendar

Earnings

Next earnings date:

Feb 21, 2025

Recent quarterly earnings:

Oct 30, 2024

Recent annual earnings:

Feb 22, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Nov 16, 2014

Analyst ratings

Recent major analysts updates

18 Dec '24 Truist Securities
Buy
17 Dec '24 Oppenheimer
Outperform
11 Dec '24 Wells Fargo
Overweight
11 Dec '24 Citigroup
Neutral
09 Dec '24 Canaccord Genuity
Buy
26 Nov '24 BTIG
Buy
20 Nov '24 Piper Sandler
Overweight
31 Oct '24 Piper Sandler
Overweight
31 Oct '24 Needham
Hold
31 Oct '24 Baird
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PEN
prnewswire.com30 December 2024

ALAMEDA, Calif., Dec. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) has announced that its management team will be presenting at the 43rd Annual J.P.

Is Penumbra (PEN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Is Penumbra (PEN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Is Penumbra (PEN) a Solid Growth Stock? 3 Reasons to Think "Yes"
PEN
zacks.com25 December 2024

Penumbra (PEN) has the potential to deliver impressive returns due to its strong growth characteristics.

Here's Why Penumbra (PEN) is a Strong Momentum Stock
Here's Why Penumbra (PEN) is a Strong Momentum Stock
Here's Why Penumbra (PEN) is a Strong Momentum Stock
PEN
zacks.com18 December 2024

The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons why you should make use of this tool.

Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why
Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why
Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why
PEN
zacks.com09 December 2024

Penumbra (PEN) is likely to do better than the market because it shows strong growth in its financial performance.

Is Penumbra Stock a Smart Buy for Your Portfolio Right Now?
Is Penumbra Stock a Smart Buy for Your Portfolio Right Now?
Is Penumbra Stock a Smart Buy for Your Portfolio Right Now?
PEN
zacks.com03 December 2024

PEN remains a focus for investors because of its strong portfolio growth and plans for international expansion.

3 Reasons Growth Investors Will Love Penumbra (PEN)
3 Reasons Growth Investors Will Love Penumbra (PEN)
3 Reasons Growth Investors Will Love Penumbra (PEN)
PEN
zacks.com21 November 2024

Penumbra (PEN) has strong growth characteristics that may allow it to significantly exceed market performance.

Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference
Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference
Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference
PEN
prnewswire.com20 November 2024

ALAMEDA, Calif., Nov. 20, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) has announced that its management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024.

Here is Why Growth Investors Should Buy Penumbra (PEN) Now
Here is Why Growth Investors Should Buy Penumbra (PEN) Now
Here is Why Growth Investors Should Buy Penumbra (PEN) Now
PEN
zacks.com05 November 2024

Penumbra (PEN) is likely to do better than the market because it shows strong growth in its financial performance.

Penumbra Q3 Earnings Beat, Margins Expand, Stock Up in After Market
Penumbra Q3 Earnings Beat, Margins Expand, Stock Up in After Market
Penumbra Q3 Earnings Beat, Margins Expand, Stock Up in After Market
PEN
zacks.com31 October 2024

The results for the third quarter show that Penumbra's thrombectomy business in the U.S. has performed well again.

Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript
Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript
Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript
PEN
seekingalpha.com30 October 2024

Penumbra, Inc. (NYSE:PEN) will hold its Q3 2024 Earnings Conference Call on October 30, 2024, at 4:30 PM ET. The call will feature company representatives including Cecilia Furlong, Adam Elsesser, Maggie Yuen, and Jason Mills. Various analysts from firms like Truist Securities, JPMorgan, and Citi will also participate in the call.

FAQ

  • What is the primary business of Penumbra?
  • What is the ticker symbol for Penumbra?
  • Does Penumbra pay dividends?
  • What sector is Penumbra in?
  • What industry is Penumbra in?
  • What country is Penumbra based in?
  • When did Penumbra go public?
  • Is Penumbra in the S&P 500?
  • Is Penumbra in the NASDAQ 100?
  • Is Penumbra in the Dow Jones?
  • When was Penumbra's last earnings report?
  • When does Penumbra report earnings?
  • Should I buy Penumbra stock now?

What is the primary business of Penumbra?

Penumbra, Inc. is a medical company focused on innovative treatment methods, which designs, develops, manufactures, and sells medical devices. The company's products are aimed at two main segments: vascular diseases and neurosurgery. In both of these markets, the company offers key products: thrombectomy systems - for removing blood clots (thrombi) and embolization systems - for treating patients with various sizes of aneurysms and other vascular and nervous disorders. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.

What is the ticker symbol for Penumbra?

The ticker symbol for Penumbra is NYSE:PEN

Does Penumbra pay dividends?

No, Penumbra does not pay dividends

What sector is Penumbra in?

Penumbra is in the Healthcare sector

What industry is Penumbra in?

Penumbra is in the Medical Devices industry

What country is Penumbra based in?

Penumbra is headquartered in United States

When did Penumbra go public?

Penumbra's initial public offering (IPO) was on 18 September 2015

Is Penumbra in the S&P 500?

No, Penumbra is not included in the S&P 500 index

Is Penumbra in the NASDAQ 100?

No, Penumbra is not included in the NASDAQ 100 index

Is Penumbra in the Dow Jones?

No, Penumbra is not included in the Dow Jones index

When was Penumbra's last earnings report?

Penumbra's most recent earnings report was on 30 October 2024

When does Penumbra report earnings?

The next expected earnings date for Penumbra is 21 February 2025

Should I buy Penumbra stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions